News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
603,697 Results
Type
Article (43120)
Company Profile (223)
Press Release (560339)
Multimedia
Podcasts (139)
Webinars (20)
Section
Business (164593)
Career Advice (2081)
Deals (30049)
Drug Delivery (131)
Drug Development (77085)
Employer Resources (156)
FDA (15114)
Job Trends (13033)
News (292807)
Policy (28799)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (2324)
Accelerated approval (33)
Adcomms (34)
Allergies (138)
Alliances (42874)
ALS (164)
Alzheimer's disease (1527)
Antibody-drug conjugate (ADC) (320)
Approvals (15337)
Artificial intelligence (518)
Autoimmune disease (148)
Automation (34)
Bankruptcy (281)
Best Places to Work (10078)
BIOSECURE Act (21)
Biosimilars (193)
Biotechnology (110)
Bladder cancer (149)
Brain cancer (60)
Breast cancer (587)
Cancer (4593)
Cardiovascular disease (401)
Career advice (1753)
Career pathing (37)
CAR-T (261)
CDC (47)
Cell therapy (685)
Cervical cancer (33)
Clinical research (66508)
Collaboration (1595)
Company closure (4)
Compensation (717)
Complete response letters (68)
COVID-19 (2561)
CRISPR (86)
C-suite (747)
Cystic fibrosis (139)
Data (5880)
Decentralized trials (2)
Denatured (35)
Depression (139)
Diabetes (446)
Diagnostics (5621)
Digital health (32)
Diversity (11)
Diversity, equity & inclusion (44)
Drug discovery (245)
Drug pricing (215)
Drug shortages (34)
Duchenne muscular dystrophy (214)
Earnings (66045)
Editorial (61)
Employer branding (20)
Employer resources (143)
Events (88403)
Executive appointments (869)
FDA (18056)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (9)
Frontotemporal dementia (17)
Funding (1359)
Gene editing (186)
Generative AI (46)
Gene therapy (588)
GLP-1 (1019)
Government (4380)
Grass and pollen (5)
Guidances (378)
Healthcare (15853)
HIV (52)
Huntington's disease (43)
IgA nephropathy (84)
Immunology and inflammation (254)
Immuno-oncology (51)
Indications (98)
Infectious disease (2823)
Inflammatory bowel disease (185)
Inflation Reduction Act (14)
Influenza (106)
Intellectual property (215)
Interviews (350)
IPO (13644)
IRA (57)
Job creations (3273)
Job search strategy (1485)
JPM (62)
Kidney cancer (16)
Labor market (76)
Layoffs (512)
Leadership (35)
Legal (6220)
Liver cancer (91)
Longevity (14)
Lung cancer (636)
Lymphoma (363)
Machine learning (38)
Management (52)
Manufacturing (757)
MASH (163)
Medical device (10537)
Medtech (10579)
Mergers & acquisitions (17317)
Metabolic disorders (1256)
Multiple sclerosis (151)
NASH (21)
Neurodegenerative disease (296)
Neuropsychiatric disorders (95)
Neuroscience (2722)
Neurotech (1)
NextGen: Class of 2026 (5698)
Non-profit (3820)
Now hiring (50)
Obesity (634)
Opinion (311)
Ovarian cancer (145)
Pain (198)
Pancreatic cancer (214)
Parkinson's disease (271)
Partnered (31)
Patents (430)
Patient recruitment (459)
Peanut (57)
People (49744)
Pharmaceutical (92)
Pharmacy benefit managers (33)
Phase 1 (20200)
Phase 2 (29263)
Phase 3 (22414)
Pipeline (4808)
Policy (298)
Postmarket research (2346)
Preclinical (8088)
Press Release (61)
Prostate cancer (243)
Psychedelics (49)
Radiopharmaceuticals (302)
Rare diseases (889)
Real estate (5056)
Recruiting (65)
Regulatory (22412)
Reports (42)
Research institute (2208)
Resumes & cover letters (321)
Rett syndrome (28)
RNA editing (20)
RSV (77)
Schizophrenia (155)
Series A (243)
Series B (181)
Service/supplier (10)
Sickle cell disease (92)
Special edition (24)
Spinal muscular atrophy (166)
Sponsored (36)
Startups (3566)
State (2)
Stomach cancer (17)
Supply chain (102)
Tariffs (100)
The Weekly (102)
Vaccines (968)
Venture capital (93)
Weight loss (441)
Women's health (72)
Worklife (18)
Date
Today (7)
Last 7 days (520)
Last 30 days (1969)
Last 365 days (26678)
2026 (2516)
2025 (26994)
2024 (31118)
2023 (34890)
2022 (45029)
2021 (48519)
2020 (46966)
2019 (40119)
2018 (30669)
2017 (29283)
2016 (28239)
2015 (32618)
2014 (25252)
2013 (20952)
2012 (22320)
2011 (23048)
2010 (20822)
Location
Africa (774)
Alabama (71)
Alaska (5)
Arizona (192)
Arkansas (12)
Asia (39075)
Australia (6189)
California (9224)
Canada (2854)
China (1074)
Colorado (396)
Connecticut (427)
Delaware (275)
Europe (85269)
Florida (1548)
Georgia (260)
Hawaii (3)
Idaho (44)
Illinois (778)
India (64)
Indiana (394)
Iowa (17)
Japan (418)
Kansas (116)
Kentucky (34)
Louisiana (19)
Maine (48)
Maryland (1172)
Massachusetts (6923)
Michigan (234)
Minnesota (474)
Mississippi (5)
Missouri (93)
Montana (28)
Nebraska (25)
Nevada (105)
New Hampshire (52)
New Jersey (2738)
New Mexico (29)
New York (2584)
North Carolina (1300)
North Dakota (8)
Northern California (4413)
Ohio (296)
Oklahoma (18)
Oregon (39)
Pennsylvania (1860)
Puerto Rico (22)
Rhode Island (45)
South America (1052)
South Carolina (35)
Southern California (3682)
Tennessee (145)
Texas (1360)
United States (33592)
Utah (248)
Vermont (1)
Virginia (258)
Washington D.C. (72)
Washington State (742)
West Virginia (3)
Wisconsin (100)
Wyoming (2)
603,697 Results for "ra pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
November 27, 2025
·
3 min read
Press Releases
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
January 28, 2026
·
3 min read
Press Releases
As mental health patients turn to AI chatbots, how can pharma lead the way?
A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.
February 5, 2026
·
1 min read
Press Releases
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
January 29, 2026
·
4 min read
Drug pricing
Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026
Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo.
January 6, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
February 4, 2026
·
9 min read
Press Releases
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
January 27, 2026
·
8 min read
Mergers & acquisitions
At JPM26, Policy and Politics Will Loom Large for Pharma as Biotech Sees the Sun
Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a break after a few tough years.
January 9, 2026
·
4 min read
·
Annalee Armstrong
Press Releases
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
June 25, 2025
·
9 min read
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
·
7 min read
·
Dan Samorodnitsky
1 of 60,370
Next
